Phase 1 N=25 Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
Psychosis
Primary: Change From Baseline in Perceived Treatment Efficacy — 2.6; 1.6; 0.5; 0.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Prostate Cancer
Primary: Progression-free Survival (PFS) at 36 Months (3 Years) — 69.2 percentage of participants
Phase 4 N=335 Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
Quality of Life · Injection Site Reaction · Adverse Drug Event
Primary: Total Number of Participants With Moderate or More Severe Fever, Chills, Myalgia, or Arthralgia in the Simultaneous Group and the Sequential Group Following Both…
N/A N=51 Clinical Study Evaluating the Safety and Effectiveness of The Tixel Fractional System in The Treatment of Periorbital Wrinkles
Wrinkle · Periorbital · Tixel 2
Primary: Percentage of Participants With Safety Adverse Events — 3.92 Percentage of Participants
N/A N=19 Muscle Synergies During Gait in Children With Cerebral Palsy Undergoing Robot-assisted Gait Therapy
Cerebral Palsy
Primary: Change in Cosine Similarity of the Muscle Synergies of the Most Affected Lower Limb — 2 percentage of muscle synergies
N/A N=8 Effects of Bodily Illusion and tDCS on SCI-related Neuropathic Pain
Neuropathic Pain
Primary: Change in Neuropathic Pain Severity — -7.3; 8.5 score on a scale
Phase 2 N=15 Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Cancer Cachexia
Primary: Change of Body Weight — 0; 0.2 kg
N/A N=31 Suicide Prevention for Sexual and Gender Minority Youth (Open Trial)
Suicide
Primary: The Interpersonal Needs Questionnaire-15 (INQ-15) - Thwarted Belongingness — 30.83; 28.13; 29.36 score on a scale
Phase 2 N=300 Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali
Malaria
Primary: Number of Participants With Adverse Events Within 7 Days After Each Vaccine Administration — 51; 43; 43 Participants
Phase 4 N=494 Personalized Treatments for Depressive Symptoms in Patients With Advanced Heart Failure
Depression · Heart Failure
Primary: Depressive Symptom Severity as Measured by the Patient Health Questionnaire (PHQ-9) Depression Scale Results at 6 Months Follow up — 14.31; 14.54; 8.09; 7.53 score on a…
N/A N=106 The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial
Medication Adherence · Asthma in Children
Primary: Mean Monthly Adherence to Inhaled Corticosteroid Regimen (Unadjusted) — 0.56; 0.50; 0.52; 0.61 proportion of prescribed doses taken
Phase 2 N=114 Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial
Prostate Cancer
Primary: Pathology Status — 2.37; 1.73 number of positive cores
N/A N=494,679 To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
Diabetes Mellitus, Type 2
Primary: Incidence Rate of Acute Pancreatitis — 10.30; 11.65 Events per 1,000 person-years
N/A N=114 REACH Implicit Bias Training Project
Communication · Bias, Racial · Relation, Doctor Patient
Primary: Feasibility of Training Measured by Participation
Phase 1 N=29 A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Psoriasis
Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…